Abstract 408P
Background
Despite the recent progress of immune therapies and multi-kinase inhibitors such as Sora, the 5-year survival rate for late-stage HCC remains dismal. The high prevalence and distinct etiology of HCC in Asia Pacific represent high unmet medical needs. Considering EGFR and MET are frequently over-expressed in HCC and often correlate with poor prognosis, we evaluated the impact of Sora on EGFR and MET expression (expr) and TME in treating late-stage HCC. We also evaluated the association of EGFR and MET expr, etiology and TME.
Methods
Total 51 HCC patients (pts) with tumor tissues before 1st-line Sora treatment (Tx) and 43 paired post- Sora samples obtained for immunohistochemistry (IHC) and RNA sequencing (RNAseq) analysis. The formalin-fixed, paraffin-embedded (FFPE) tissues were analyzed for EGFR and MET expr by IHC using EGFR D38B1 and MET SP44 antibodies. Staining intensity was scored on a scale of 0, 1+, 2+ and 3+. RNAseq was successfully conducted in 60 FFPE tissues (33 pre- and 27 post- Sora samples) by TruSeq RNA Access library preparation. R package immunedeconv was used for TME estimation.
Results
The median duration of Sora Tx was 126 days for study group. Overall, H score of EGFR and MET expr was higher in post- Sora than in pre- Sora samples (Median value: EGFR 100 vs 55; MET 110 vs 85). On a pt level, increased EGFR and MET expr in IHC>=2+ was observed respectively in 53% and 41% of HCC pts post Sora Tx. Interestingly, H score of MET expr in HBV+ group was higher than that in HBV- group (p = 0.003). MET gene expr also showed similar trend (p = 0.002) but not for EGFR. Different cut-off for EGFR and MET IHC expr showed similar results as above. Furthermore, a trend of positive correlation was observed between robust MET IHC staining and myeloid dendritic cell activated score (RNAseq) post Sora Tx (n = 26).
Conclusions
This is the first time to report EGFR and MET IHC expr from pre- and post- Sora HCC samples using different cut off scores. EGFR and MET expr was higher in post- Sora than in pre- Sora samples. MET expr in HBV+ group was higher than that in HBV- group. The mechanisms and clinical significance of these observations warrant further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Disclosure
C.J. Yen: Non-Financial Interests, Institutional, Principal Investigator: National Cheng Kung University college of medicine- National Cheng Kung University Hospital. M. Qing, X. Lyu, M. Gormley, M. Xia: Financial Interests, Personal, Full or part-time Employment: Janssen Research & Development . J. Curtin, F. Yang, L. Zhou: Financial Interests, Institutional, Full or part-time Employment: Janssen Research & Development.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract